Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Itepekimab SAR440340
Placebo
Locations
248
United States
University of Alabama at Birmingham Site Number : 8400012
Birmingham, Alabama, United States
Jasper Summit Research Site Number : 8400178
Jasper, Alabama, United States
Chandler Clinical Trials (Elite Clinical Network) Site Number : 8400034
Chandler, Arizona, United States
Pulmonary Associates Site Number : 8400392
Phoenix, Arizona, United States
Noble Clinical Research Site Number : 8400182
Tucson, Arizona, United States
Tucson Clinical Research Institute Site Number : 8400431
Tucson, Arizona, United States
Start Date
December 16, 2020
Primary Completion Date
April 11, 2025
Completion Date
August 27, 2025
Last Updated
April 15, 2026
NCT05746039
NCT07190209
NCT07307781
NCT07073950
NCT07509606
NCT07451977
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions